Purpose. The 3. The dose-limiting toxicity was myelosuppression.
Introduction
Etoposide ) is a semi-synthetic derivative of podophyllotoxin. It first underwent clinical trials 20 years ago. It has significant activity in lymphoma, leukaemia and small cell lung cancer and is included in most standard regimens for the treatment of germ cell tumours. It acts primarily by inhibition of topoisomerase II resulting in doubleand single-strand DNA breaks.
The initial trials of etoposide as a single agent in the treatment of soft tissue sarcoma (STS), almost all carried out in pretreated patients, have been disappointing. Welt et al. reported a dose escalation study in pretreated patients with a 3-day alternating schedule. 2 The starting dose was 120 mg m-2 given intravenously every other day for three doses, repeated every 3 weeks, increasing to a maximum of 240 mg m-per dose. While toxicity was low, there was only one minor response, which included complete resolution of lung metastases, and 4/26 patients had stable disease. Similarly, a phase II EORTC study using a treatment schedule of 130 mg m-po daily for 5 days every 3 weeks, in mostly heavily pretreated patients, reported only one partial response (PR), which lasted 19 months, in 29 patients. 3 However, responses have been reported using more prolonged exposure. Hainsworth et al. 4 Response to prior chemotherapy the 72-h infusion were measured, the mean plasma level has been calculated (16/20 
